Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XTR015
- Development stage
- Unknown
- Lead developer
- Sinotau Pharmaceutical Group
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
XTR015 is a copper-64 (64Cu) labeled radiopharmaceutical developed by Sinotau Pharmaceutical Group for the positron emission tomography (PET) imaging of cancers expressing somatostatin receptors (SSTR). It is the first 64Cu-labeled SSTR-targeted PET radioligand to receive Investigational New Drug (IND) approval in China. Compared to traditional gallium-68 (68Ga) labeled alternatives, XTR015 offers several clinical advantages, including a significantly longer half-life (12.7 hours versus 67.7 minutes) and lower positron energy, which results in improved spatial resolution and an extended imaging window of one to three hours post-injection. The drug is primarily utilized for the diagnosis, staging, and management of neuroendocrine tumors and other SSTR-positive malignancies.
- Other names
- 64Cu-labeled SSTR-targeted PET radioligand64Cu-SSTR PET
02
Targets
SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on XTR015.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XTR015.